<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Chin Med J (Engl)</journal-id><journal-id journal-id-type="iso-abbrev">Chin. Med. J</journal-id><journal-id journal-id-type="publisher-id">CMJ</journal-id><journal-title-group><journal-title>Chinese Medical Journal</journal-title></journal-title-group><issn pub-type="ppub">0366-6999</issn><publisher><publisher-name>Medknow Publications &#x00026; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26608978</article-id><article-id pub-id-type="pmc">4795249</article-id><article-id pub-id-type="publisher-id">CMJ-128-3003</article-id><article-id pub-id-type="doi">10.4103/0366-6999.168963</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>An Interdisciplinary Nutrition Support Team Improves Clinical and Hospitalized Outcomes of Esophageal Cancer Patients with Concurrent Chemoradiotherapy</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Cong</surname><given-names>Ming-Hua</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="author-notes" rid="fn1"/></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Shu-Luan</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="author-notes" rid="fn1"/></contrib><contrib contrib-type="author"><name><surname>Cheng</surname><given-names>Guo-Wei</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Jin-Ying</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Song</surname><given-names>Chen-Xin</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Deng</surname><given-names>Ying-Bing</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Shang</surname><given-names>Wei-Hu</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Di</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Xue-Hui</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Wei-Wei</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Lu</surname><given-names>Shi-Yan</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Yu</surname><given-names>Lei</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1"/></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Comprehensive Oncology, Chinese Academy of Medical Sciences Cancer Hospital, Beijing 100021, China</aff><aff id="aff2"><label>2</label>Department of General Medicine, Huanxing Cancer Hospital of Chaoyang District, Beijing 100122, China</aff><aff id="aff3"><label>3</label>Department of Radiotherapy, Huanxing Cancer Hospital of Chaoyang District, Beijing 100122, China</aff><aff id="aff4"><label>4</label>Department of Clinical Nutrition, Chinese Academy of Medical Sciences Cancer Hospital, Beijing 100021, China</aff><aff id="aff5"><label>5</label>Department of Clinical Nutrition, Peking Union Medical College Hospital of Chinese Academy of Medical Sciences, Beijing 100730, China</aff><author-notes><fn id="fn1"><p>Ming-Hua Cong and Shu-Luan Li contributed equally to this study.</p></fn><corresp id="cor1"><bold>Address for correspondence:</bold> Dr. Lei Yu, Department of Comprehensive Oncology, Chinese Academy of Medical Sciences Cancer Hospital, Beijing 100021, China E-Mail: <email xlink:href="yulei01578@163.com">yulei01578@163.com</email></corresp></author-notes><pub-date pub-type="ppub"><day>20</day><month>11</month><year>2015</year></pub-date><volume>128</volume><issue>22</issue><fpage>3003</fpage><lpage>3007</lpage><history><date date-type="received"><day>17</day><month>7</month><year>2015</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2015 Chinese Medical Journal</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.</license-p></license></permissions><abstract><sec id="st1"><title>Background:</title><p>The prevalence of malnutrition is very high in patients with cancer. The purpose of this study was to investigate whether or not a nutrition support team (NST) could benefit esophageal cancer patients undergoing chemoradiotherapy (CRT).</p></sec><sec id="st2"><title>Methods:</title><p>Between June 2012 and April 2014, 50 esophageal cancer patients undergoing concurrent CRT were randomly assigned into two groups: The NST group and the control group. The nutritional statuses of 25 patients in the NST group were managed by the NST. The other 25 patients in the control group underwent the supervision of radiotherapy practitioners. At the end of the CRT, nutritional status, the incidence of complications, and completion rate of radiotherapy were evaluated. Besides, the length of hospital stay (LOS) and the in-patient cost were also compared between these two groups.</p></sec><sec id="st3"><title>Results:</title><p>At the completion of CRF, the nutritional status in the NST group were much better than those in the control group, as evidenced by prealbumin (ALB), transferrin, and ALB parameters (<italic>P</italic> = 0.001, 0.000, and 0.000, respectively). The complication incidences, including bone marrow suppression (20% vs. 48%, <italic>P</italic> = 0.037) and complications related infections (12% vs. 44%, <italic>P</italic> = 0.012), in the NST group were lower and significantly different from the control group. In addition, only one patient in the NST group did not complete the planned radiotherapy while 6 patients in the control group had interrupted or delayed radiotherapy (96% vs. 76%, <italic>P</italic> = 0.103). Furthermore, the average LOS was decreased by 4.5 days (<italic>P</italic> = 0.001) and in-patient cost was reduced to 1.26 &#x000b1; 0.75 thousand US dollars person-times (<italic>P</italic> &#x0003e; 0.05) in the NST group.</p></sec><sec id="st4"><title>Conclusions:</title><p>A NST could provide positive effects in esophageal cancer patients during concurrent CRT on maintaining their nutrition status and improving the compliance of CRF. Moreover, the NST could be helpful on reducing LOS and in-patient costs.</p></sec></abstract><kwd-group><kwd>Chemoradiotherapy</kwd><kwd>Complication</kwd><kwd>Esophageal Cancer</kwd><kwd>Nutrition Support Team</kwd><kwd>Prognosis</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title>I<sc>NTRODUCTION</sc></title><p>Esophageal cancer is one of the most common cancers in the world, with diagnoses of more than 480,000 patients and 400,000 deaths annually.[<xref rid="ref1" ref-type="bibr">1</xref>] The incidence and mortality rate of esophageal cancer rises continuously, especially in the mainland of China. Surgery and chemoradiotherapy (CRT) are the important strategies for the treatment of esophageal cancer.[<xref rid="ref2" ref-type="bibr">2</xref>] It is reported that 79% of esophageal cancer patients experience malnutrition, which is caused mainly by anorexia and dysphagia, before the treatment starts.[<xref rid="ref3" ref-type="bibr">3</xref><xref rid="ref4" ref-type="bibr">4</xref>] The dysphagia-related nutrition deficiency could be even worse during the treatment and as a result, weight lost would occur. Furthermore, malnutrition is a sign of poor outcomes in cancer patients, which negatively affected the response to therapy, the length of hospital stay (LOS), the quality of life, complications, infections, and the survival rate.[<xref rid="ref5" ref-type="bibr">5</xref><xref rid="ref6" ref-type="bibr">6</xref><xref rid="ref7" ref-type="bibr">7</xref>] Therefore, it is necessary to implement cancer patients&#x02019; treatment on malnutrition.</p><p>Nutritional intervention could improve clinical outcomes of cancer patients, including esophageal cancer.[<xref rid="ref3" ref-type="bibr">3</xref>] Besides, nutritional support was mainly given to patients by the routes of oral nutritional supplements (ONS), the enteral nutrition (EN), and the parenteral nutrition (PN). It has been shown clinical benefits of nutritional intervention via EN in esophageal cancer patients who are undergoing radiochemotherapy (RCT), which guiding clinicians using EN to enhance the nutritional status and functional capacity.[<xref rid="ref8" ref-type="bibr">8</xref>] The rationale for nutritional support is to improve nutritional status, modulate inflammatory responses, decrease the risk of infection, and enhance the quality of life. In order to provide more reasonable and effective nutritional intervention, many countries have introduced nutrition support team (NST) in hospitals.[<xref rid="ref9" ref-type="bibr">9</xref>] Besides, in order to provide nutrition supports, the European Society of Parenteral and Enteral Nutrition (ESPEN) recommends the contribution of multidisciplinary NST.</p><p>NST has been found to reduce the incidence of complications, in-patient costs, and mortality rates. Based on our knowledge, few randomized control trials have evaluated the effect of NST in esophageal cancer patients with concurrent CRT. NST was established in the Huanxing Hospital (Beijing, China) in April 2012. Team members includes: Physicians, registered dietitians, pharmacologists, nurses, and managers. The major goals of the NST were to normalize the medical nutrition therapy (MNT) and to emphasize on the nutrition care process during the MNT. The functional area includes the office, the metabolism laboratory, and configured rooms for dietary, EN, PN, etc. The purpose of this study was to investigate the clinical therapy effects of NST and to provide NST services to esophageal patients, who are treated with CRT.</p></sec><sec sec-type="methods" id="sec1-2"><title>M<sc>ETHODS</sc></title><sec id="sec2-1"><title>Patients&#x02019; eligibility</title><p>The patients were recruited in Department of Comprehensive Oncology, Chinese Academy of Medical Sciences Cancer Hospital (CAMSCH), including a total of 50 esophageal cancer in-patients, between June 2012 and April 2014. The study was designed and conducted in accordance with the <italic>Declaration of Helsinki</italic> and was approved by the Institutional Board and Ethics Committee of CAMSCH.</p><p>The patients were eligible to participate in the study if they had confirmed pathological result of primarily phase III esophageal cancer (squamous cell carcinomas) with a planned treatment by radiotherapy combined chemotherapy, weight loss &#x0003c;10% and diet decrease (but &#x0003e;60% targeted feeding volume), the patient-generated subjective global assessment (PG-SGA) score &#x02265;4 points, and accepted written informed consent.</p><p>Exclusion criteria were being severe malnutrition (weight loss &#x0003e;10%, blood albumin [ALB] &#x0003c;30 g/L, or body mass index [BMI] &#x0003c;18.5 kg/m<sup>2</sup>), having serious heart, lung or brain disease, with chronic hepatitis, cirrhosis, chronic nephritis or renal insufficiency, complicated with infectious fever, and EN or PN intolerance.</p></sec><sec id="sec2-2"><title>Protocol design</title><p>Based on the different nutrition intervention methods, 50 eligible patients were randomly assigned into the NST group and the control group, all of whom received the same CRT treatment for two cycles of chemotherapy followed by the radiotherapy. The study was stopped at the end of radiotherapy. The standard anti-cancer therapy included concurrent CRT with cisplatin/carboplatin with paclitaxel and radiotherapy according to the center's current practice 50&#x02013;60 Gy/2 Gy/25&#x02013;30 f. Nutritional support included diet counseling, ONS, EN, and PN.</p><p>The patients in the NST group met with a member of the NST, which consisted of board-certified dietitians and advanced-practice nurses. Specific attention was paid to nutrition risk screening, nutrition assessment, nutrition intervention, nutrition monitoring, and evaluation via standardized clinical nutrition process. The energy intake goal was 30&#x02013;35 kcal&#x000b7;kg<sup>&#x02212;1</sup>&#x000b7;d<sup>&#x02212;1</sup> and the macronutrient intakes were protein: 1.5 g/kg (20%), fat: 1.3 g/kg (40%), and carbohydrates: 3 g/kg (40%). Micronutrients&#x02019; intakes were based on the conventional proportional. On the other hand, the patients in the control group were conducted by chief physicians and were not scheduled to meet with the NST service. The nutrition therapy for the control group mainly included ONS and PN without intake goals.</p></sec><sec id="sec2-3"><title>Data collection</title><p>All the following parameters were measured in the beginning and the end of the study.</p><p><bold>Nutritional and blood determinations</bold></p><p>Height (m) and weight (kg) were measured and BMI were calculated as BMI = kg/m<sup>2</sup>. The quantity of prealbumin (PALB), transferrin, and ALB were tested from the peripheral blood.</p><p><bold>Incidence of complications</bold></p><p>The number of hemoglobin (Hgb), leukocyte, platelet (PLT) were counted automatically. Infections related to complications were identified and recorded, including catheter related infection, pulmonary infection, local skin infection, and mucosal inflammation infection. Bone marrow depression were observed and graded according to the National Cancer Institute-Common Toxicity Criteria version 3.0.[<xref rid="ref10" ref-type="bibr">10</xref>]</p><p><bold>Clinical outcomes</bold></p><p>The completion rates of therapy, the LOS, and the in-patient cost were recorded during the study.</p></sec><sec id="sec2-4"><title>Statistical analysis</title><p>All statistical analysis was performed with SPSS, version 20.0 (SPSS Inc., Chicago, IL, USA). Categorical variables were described by percentages and compared using Chi-square test. Continuous variables were described by mean &#x000b1; standard deviation (SD) and compared using two-sample Student's <italic>t</italic>-test or analysis of variance (ANOVA), when appropriate. A two-tailed <italic>P</italic> &#x0003c; 0.05 was considered statistically significant.</p></sec></sec><sec sec-type="results" id="sec1-3"><title>R<sc>ESULTS</sc></title><sec id="sec2-5"><title>Baseline characteristics of the patients</title><p>A total of 50 patients with esophageal cancer were selected randomly in the study. Baseline characteristics of patients were shown in <xref ref-type="table" rid="T1">Table 1</xref>. There were 25 patients in the NST group (18 males, 7 females) and 25 patients in the control group (17 males, 8 females). Homogeneity analyses for baseline characteristics were performed for all the patients&#x02019; data sets [<xref ref-type="table" rid="T1">Table 1</xref>]. Baseline characteristics (age, gender, weight, BMI, PG-SGA value, cancer diagnosis, treatment protocols, and hematological parameters) were well-balanced between the two groups. However, comparing with the control group, during the CRT treatment course, more patients in the NST group used tube feedings (68% vs. 32%, <italic>P</italic> = 0.023).</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Baseline characteristics of the esophageal cancer patients undergoing concurrent CRT in both NST and control groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Variables</th><th align="center" rowspan="1" colspan="1">NST group (<italic>n</italic> = 25)</th><th align="center" rowspan="1" colspan="1">Control group (<italic>n</italic> = 25)</th><th align="center" rowspan="1" colspan="1"><italic>t</italic> or X<sup>2</sup></th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="center" rowspan="1" colspan="1">51.36 &#x000b1; 11.02</td><td align="center" rowspan="1" colspan="1">50.88 &#x000b1; 8.80</td><td align="center" rowspan="1" colspan="1">0.170</td><td align="center" rowspan="1" colspan="1">0.866</td></tr><tr><td align="left" rowspan="1" colspan="1">Gender (<italic>n</italic>)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.095*</td><td align="center" rowspan="1" colspan="1">1.000</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Male</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Female</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Number of squamous esophageal carcinoma cases (<italic>n</italic>)</td><td align="center" rowspan="1" colspan="1">25</td><td align="center" rowspan="1" colspan="1">25</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Stage (<italic>n</italic>)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.402</td><td align="center" rowspan="1" colspan="1">0.818</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;IIIa</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;IIIb</td><td align="center" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;IIIc</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Anti-cancer therapy</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Chemotherapy (<italic>n</italic>)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.080</td><td align="center" rowspan="1" colspan="1">0.777</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Paclitaxel + cisplatin</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Paclitaxel + carboplatin</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Radiation dose (Gy)</td><td align="center" rowspan="1" colspan="1">58.2 &#x000b1; 3.4</td><td align="center" rowspan="1" colspan="1">57.5 &#x000b1; 3.9</td><td align="center" rowspan="1" colspan="1">&#x02212;0.688</td><td align="center" rowspan="1" colspan="1">0.495</td></tr><tr><td align="left" rowspan="1" colspan="1">PG-SGA</td><td align="center" rowspan="1" colspan="1">6.64 &#x000b1; 1.77</td><td align="center" rowspan="1" colspan="1">6.84 &#x000b1; 1.18</td><td align="center" rowspan="1" colspan="1">&#x02212;0.469</td><td align="center" rowspan="1" colspan="1">0.641</td></tr><tr><td align="left" rowspan="1" colspan="1">Weight (kg)</td><td align="center" rowspan="1" colspan="1">57.84 &#x000b1; 8.50</td><td align="center" rowspan="1" colspan="1">56.12 &#x000b1; 8.17</td><td align="center" rowspan="1" colspan="1">0.729</td><td align="center" rowspan="1" colspan="1">0.469</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">20.52 &#x000b1; 2.12</td><td align="center" rowspan="1" colspan="1">20.84 &#x000b1; 2.19</td><td align="center" rowspan="1" colspan="1">&#x02212;0.524</td><td align="center" rowspan="1" colspan="1">0.603</td></tr><tr><td align="left" rowspan="1" colspan="1">WBC (g/L)</td><td align="center" rowspan="1" colspan="1">5.54 &#x000b1; 1.26</td><td align="center" rowspan="1" colspan="1">5.99 &#x000b1; 1.47</td><td align="center" rowspan="1" colspan="1">&#x02212;1.180</td><td align="center" rowspan="1" colspan="1">0.244</td></tr><tr><td align="left" rowspan="1" colspan="1">Hgb (g/L)</td><td align="center" rowspan="1" colspan="1">10.77 &#x000b1; 1.89</td><td align="center" rowspan="1" colspan="1">10.26 &#x000b1; 1.33</td><td align="center" rowspan="1" colspan="1">1.102</td><td align="center" rowspan="1" colspan="1">0.276</td></tr><tr><td align="left" rowspan="1" colspan="1">PLT (g/L)</td><td align="center" rowspan="1" colspan="1">260.72 &#x000b1; 45.93</td><td align="center" rowspan="1" colspan="1">262.23 &#x000b1; 53.51</td><td align="center" rowspan="1" colspan="1">&#x02212;0.107</td><td align="center" rowspan="1" colspan="1">0.915</td></tr><tr><td align="left" rowspan="1" colspan="1">PALB (mg/L)</td><td align="center" rowspan="1" colspan="1">155.74 &#x000b1; 28.15</td><td align="center" rowspan="1" colspan="1">157.47 &#x000b1; 43.40</td><td align="center" rowspan="1" colspan="1">&#x02212;0.168</td><td align="center" rowspan="1" colspan="1">0.867</td></tr><tr><td align="left" rowspan="1" colspan="1">Transferrin (g/L)</td><td align="center" rowspan="1" colspan="1">2.41 &#x000b1; 0.33</td><td align="center" rowspan="1" colspan="1">2.33 &#x000b1; 0.47</td><td align="center" rowspan="1" colspan="1">0.683</td><td align="center" rowspan="1" colspan="1">0.498</td></tr><tr><td align="left" rowspan="1" colspan="1">ALB (g/L)</td><td align="center" rowspan="1" colspan="1">35.36 &#x000b1; 2.55</td><td align="center" rowspan="1" colspan="1">35.80 &#x000b1; 3.72</td><td align="center" rowspan="1" colspan="1">&#x02212;0.488</td><td align="center" rowspan="1" colspan="1">0.628</td></tr><tr><td align="left" rowspan="1" colspan="1">Nutritional support (<italic>n</italic>)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Tube feeding</td><td align="center" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">6.480*</td><td align="center" rowspan="1" colspan="1">0.023</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Diet &#x000b1; ONS &#x000b1; SPN</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn><p>Values are expressed as <italic>n</italic> or mean &#x000b1; SD. *Chi-square test was used; others were used <italic>t</italic>-test. CRT: Chemoradiotherapy; PG-SGA: Patient-generated subjective global assessment; BMI: Body mass index; WBC: White blood cell; Hgb: Hemoglobin; PLT: Platelets; PALB: Prealbumin; ALB: Albumin; ONS: Oral nutritional supplements; SPN: Supplementary parenteral nutrition; NST: Nutrition support team; SD: Standard deviation.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec2-6"><title>Nutritional status</title><p>The results showed that the NST group had better weight maintenance data compared to the control group (NST group: 0.36 &#x000b1; 2.16, <italic>P</italic> = 0.412; and control group: &#x02212;2.44 &#x000b1; 2.60, <italic>P</italic> = 0.000). Besides, changes of weight between the two groups had a significant difference [<italic>P</italic> = 0.000; <xref ref-type="table" rid="T2">Table 2</xref>].</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Changes in the characteristics of patients before and after the treatments</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Variables</th><th align="center" rowspan="1" colspan="1">Baseline</th><th align="center" rowspan="1" colspan="1">End</th><th align="center" rowspan="1" colspan="1">Change</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Weight (kg)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;NST group</td><td align="center" rowspan="1" colspan="1">57.84 &#x000b1; 8.50</td><td align="center" rowspan="1" colspan="1">58.20 &#x000b1; 8.05</td><td align="center" rowspan="1" colspan="1">0.36 &#x000b1; 2.16<sup>&#x02020;</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Control group</td><td align="center" rowspan="1" colspan="1">56.12 &#x000b1; 8.17</td><td align="center" rowspan="1" colspan="1">53.68 &#x000b1; 8.06*</td><td align="center" rowspan="1" colspan="1">&#x02212;2.44 &#x000b1; 2.60</td></tr><tr><td align="left" rowspan="1" colspan="1">ALB (g/L)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;NST group</td><td align="center" rowspan="1" colspan="1">35.36 &#x000b1; 2.55</td><td align="center" rowspan="1" colspan="1">35.36 &#x000b1; 3.95</td><td align="center" rowspan="1" colspan="1">0.00 &#x000b1; 4.57<sup>&#x02020;</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Control group</td><td align="center" rowspan="1" colspan="1">35.80 &#x000b1; 3.72</td><td align="center" rowspan="1" colspan="1">30.00 &#x000b1; 3.82*</td><td align="center" rowspan="1" colspan="1">&#x02212;5.80 &#x000b1; 4.79</td></tr><tr><td align="left" rowspan="1" colspan="1">PALB (mg/L)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;NST group</td><td align="center" rowspan="1" colspan="1">155.74 &#x000b1; 28.15</td><td align="center" rowspan="1" colspan="1">235.71 &#x000b1; 48.02*</td><td align="center" rowspan="1" colspan="1">79.98 &#x000b1; 57.54<sup>&#x02020;</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Control group</td><td align="center" rowspan="1" colspan="1">157.47 &#x000b1; 43.40</td><td align="center" rowspan="1" colspan="1">174.90 &#x000b1; 42.07</td><td align="center" rowspan="1" colspan="1">17.43 &#x000b1; 66.52</td></tr><tr><td align="left" rowspan="1" colspan="1">Transferrin (g/L)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;NST group</td><td align="center" rowspan="1" colspan="1">2.41 &#x000b1; 0.33</td><td align="center" rowspan="1" colspan="1">2.77 &#x000b1; 0.67*</td><td align="center" rowspan="1" colspan="1">0.36 &#x000b1; 0.67<sup>&#x02020;</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Control group</td><td align="center" rowspan="1" colspan="1">2.33 &#x000b1; 0.47</td><td align="center" rowspan="1" colspan="1">1.91 &#x000b1; 0.44*</td><td align="center" rowspan="1" colspan="1">&#x02212;0.43 &#x000b1; 0.61</td></tr><tr><td align="left" rowspan="1" colspan="1">WBC (g/L)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;NST group</td><td align="center" rowspan="1" colspan="1">5.54 &#x000b1; 1.26</td><td align="center" rowspan="1" colspan="1">4.98 &#x000b1; 2.18</td><td align="center" rowspan="1" colspan="1">&#x02212;0.56 &#x000b1; 2.30<sup>&#x02020;</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Control group</td><td align="center" rowspan="1" colspan="1">5.99 &#x000b1; 1.47</td><td align="center" rowspan="1" colspan="1">3.30 &#x000b1; 2.23*</td><td align="center" rowspan="1" colspan="1">&#x02212;2.69 &#x000b1; 3.13</td></tr><tr><td align="left" rowspan="1" colspan="1">Hgb (g/L)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;NST group</td><td align="center" rowspan="1" colspan="1">10.77 &#x000b1; 1.89</td><td align="center" rowspan="1" colspan="1">10.18 &#x000b1; 1.62</td><td align="center" rowspan="1" colspan="1">&#x02212;0.59 &#x000b1; 1.96</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Control group</td><td align="center" rowspan="1" colspan="1">10.26 &#x000b1; 1.33</td><td align="center" rowspan="1" colspan="1">9.11 &#x000b1; 1.20*</td><td align="center" rowspan="1" colspan="1">&#x02212;1.15 &#x000b1; 0.99</td></tr><tr><td align="left" rowspan="1" colspan="1">PLT (g/L)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;NST group</td><td align="center" rowspan="1" colspan="1">260.72 &#x000b1; 45.93</td><td align="center" rowspan="1" colspan="1">241.51 &#x000b1; 59.66</td><td align="center" rowspan="1" colspan="1">&#x02212;19.21 &#x000b1; 69.24<sup>&#x02020;</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Control group</td><td align="center" rowspan="1" colspan="1">262.23 &#x000b1; 53.51</td><td align="center" rowspan="1" colspan="1">185.80 &#x000b1; 95.73*</td><td align="center" rowspan="1" colspan="1">&#x02212;76.44 &#x000b1; 98.09</td></tr></tbody></table><table-wrap-foot><fn><p>Values are expressed as mean &#x000b1; SD. *<italic>P</italic>&#x0003c;0.05 when compared with baseline values in each group; <sup>&#x02020;</sup><italic>P</italic>&#x0003c;0.05 when compared with control group. PALB: Prealbumin; ALB: Albumin; WBC: White blood cell; Hgb: Hemoglobin; PLT: Platelets; SD: Standard deviation; NST: Nutrition support team.</p></fn></table-wrap-foot></table-wrap><p>After treatment, PALB in both groups increased. However, a significant increase in PALB was observed in NST group (79.98 &#x000b1; 57.54, <italic>P</italic> = 0.000) while no significant difference (17.43 &#x000b1; 66.52, <italic>P</italic> = 0.203) was found in the control group. In addition, changes of PALB between the two groups had a significant difference [<italic>P</italic> = 0.001; <xref ref-type="table" rid="T2">Table 2</xref>].</p><p>Compared with baseline, the transferrin of the NST group increased significantly (0.36 &#x000b1; 0.67, <italic>P</italic> = 0.013), whereas transferrin in the control group decreased significantly (&#x02212;0.43 &#x000b1; 0.61, <italic>P</italic> = 0.002). The changes of transferrin between the two groups had a significant difference [<italic>P</italic> = 0.000; <xref ref-type="table" rid="T2">Table 2</xref>].</p><p>ALB in NST group remained almost the same (0.00 &#x000b1; 4.57, <italic>P</italic> = 1.000). In contrast, ALB in the control group decreased significantly (&#x02212;5.80 &#x000b1; 4.79, <italic>P</italic> = 0.000). The changes in ALB had a significant difference between both groups [<italic>P</italic> = 0.000; <xref ref-type="table" rid="T2">Table 2</xref>].</p><p>In the NST group, white blood cell (WBC), Hgb, and PLT did not decline significantly (<italic>P</italic> = 0.238, 0.145, and 0.178, respectively). On the contrary, all these three levels in the control group had a significant decrease (<italic>P</italic> = 0.000, 0.000, and 0.001, respectively). Furthermore, the changes of WBC and PLT had a significant difference between these two groups (WBC: &#x02212;0.56 &#x000b1; 2.30 vs. &#x02212;2.69 &#x000b1; 3.13, <italic>P</italic> = 0.008; PLT: &#x02212;19.21 &#x000b1; 69.24 vs. &#x02212;76.44 &#x000b1; 98.09, <italic>P</italic> = 0.021), and the NST group tended to have a greater Hgb than control group after the treatment (&#x02212;0.59 &#x000b1; 1.96 vs. &#x02212;1.15 &#x000b1; 0.99, <italic>P</italic> = 0.205) [<xref ref-type="table" rid="T2">Table 2</xref>].</p><p>The incidences of bone marrow suppression (Grade II and above) and complications related infection were both lower in the NST group than in the control group. There were significant differences in the percentage of patients experienced bone marrow suppression (20% vs. 48%, <italic>P</italic> = 0.037) and complications related infection (12% vs. 44%, <italic>P</italic> = 0.012) [<xref ref-type="table" rid="T3">Table 3</xref>].</p><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Complication incidence and completion rates of therapy</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Variables</th><th align="center" rowspan="1" colspan="1">NST group</th><th align="center" rowspan="1" colspan="1">Control group</th><th align="center" rowspan="1" colspan="1"><italic>&#x003c7;</italic><sup>2</sup></th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Bone marrow suppression</td><td align="center" rowspan="1" colspan="1">5 (20)</td><td align="center" rowspan="1" colspan="1">12 (48)</td><td align="center" rowspan="1" colspan="1">4.367</td><td align="center" rowspan="1" colspan="1">0.037</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;(Grade II and above)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Complications</td><td align="center" rowspan="1" colspan="1">3 (12)</td><td align="center" rowspan="1" colspan="1">11 (44)</td><td align="center" rowspan="1" colspan="1">6.349</td><td align="center" rowspan="1" colspan="1">0.012</td></tr><tr><td align="left" rowspan="1" colspan="1">Completion rates</td><td align="center" rowspan="1" colspan="1">24 (96)</td><td align="center" rowspan="1" colspan="1">19 (76)</td><td align="center" rowspan="1" colspan="1">2.658</td><td align="center" rowspan="1" colspan="1">0.103</td></tr></tbody></table><table-wrap-foot><fn><p>Values are expressed as <italic>n</italic> (%). <italic>P</italic> values were calculated using the Chi-square test. NST: Nutrition support team.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec2-7"><title>Completion rates of therapy</title><p>There was only one patient in the NST group who did not complete the treatment plan while 6 patients in control group experienced treatment interruptions (dose reductions or delays). Although there was no significantly difference between the two groups, the completion rates of therapy was higher in the NST group than control group (96% vs. 76%, <italic>P</italic> = 0.103) [<xref ref-type="table" rid="T3">Table 3</xref>].</p></sec><sec id="sec2-8"><title>Length of hospital stay and hospitalization cost</title><p>At last, the average LOS and the in-patient cost were compared between the two groups. By comparing to the control group, the average LOS of patients in the NST group decreased by 4.5 days (45.68 &#x000b1; 3.87 vs. 50.16 &#x000b1; 5.38 days, <italic>t</italic> = &#x02212;3.382, <italic>P</italic> = 0.001) and the in-patient cost reduced 1.3 thousand dollars person-times (16.95 &#x000b1; 2.50 vs. 18.22 &#x000b1; 2.80 thousand dollars, <italic>t</italic> = &#x02212;1.683, <italic>P</italic> = 0.099) (Student's <italic>t</italic>-test).</p></sec></sec><sec sec-type="discussion" id="sec1-4"><title>D<sc>ISCUSSION</sc></title><p>The prevalence of malnutrition, caused by dysphagia and anorexia, is high in patients with esophageal cancer.[<xref rid="ref11" ref-type="bibr">11</xref>] During the CRT, some patients experienced malnutrition/cachexia-related complications, which affected the therapy outcomes negatively.[<xref rid="ref12" ref-type="bibr">12</xref>] In our study, a significant difference between the two groups on nutritional status and blood parameters after CRT for about 45 days was occurred. Normalized nutritional support through the NST has showed more effective roles on improving treatment compliances and nutritional status than through the control group.</p><p>In-patients&#x02019; nutritional status in the NST group were improved or maintained, yet the status decreased significantly in the control group during CRT. As we known, PALB was associated with dietary intake when synthetic functions were normal in the liver. Moreover, PALB is suggested as a sensitive nutritional biomarker for evaluating the nutritional status of esophageal cancer patients undergoing concurrent CRT.[<xref rid="ref13" ref-type="bibr">13</xref>] The patients in both groups had a low level of PALB and transferrin with normal liver function before treatment, which was caused by inadequate intake. After treatment, PALB and transferrin increased significantly in the patients of NST group while decreased or did not change in control group, suggesting NST has benefits on dietary intake and nutritional status.</p><p>Bone marrow suppression was one of the most common complications during CRT due to the decreasing production of blood cells. In the control group, WBC, Hgb, and PLT decreased significantly, associated with the high incidence of bone marrow suppression. In stark contrast, these three parameters corresponded to low incidence in the NST group. The results suggested that the incidence of bone marrow suppression decreased significantly in patients with better nutritional status, although simple nutrition support could not improve bone marrow suppression during CRT.</p><p>Several studies demonstrated that malnutrition was associated with high occurrence of complications related infection.[<xref rid="ref14" ref-type="bibr">14</xref>] Our results also showed clearly that less patients in NST group experienced complications related infection compared with the control group. Furthermore, the LOS and the in-patient cost were both increased because of the complications related infection in the control group.</p><p>The outcomes of locally advanced esophageal cancer patients by concurrent RCT were related to the nutritional status and the dosage of RCT. However, chemotherapy or radiotherapy for cancer patients were often delayed or terminated due to complications, significantly affecting the outcomes.[<xref rid="ref4" ref-type="bibr">4</xref>] Besides, the prolonged treatment caused by interrupting radiotherapy was also associated with a poor prognosis. Compared with 76% patients in the control group, 96% patients in NST group completed the RCT plan, suggesting that normalized nutritional support through NST provided better RCT compliance.</p><p>More patients in NST group used tube feeding than in the control group. EN via tube feeding was recommended by ESPEN for esophageal cancer patients, who could not eat regular food, were likely to have mucositis in the course of radiotherapy, which was benefit to nutritional status and to improve prognosis.[<xref rid="ref15" ref-type="bibr">15</xref>] However, this recommendation was not widely used in clinical practice.</p><p>In conclusion, our results indicated that nutrition management via NST was conducive to maintain nutritional status, improve RCT compliance and tolerability, and reduce the LOS and the in-patient cost for esophageal cancer patients concurrent RCT. In future, we will pay more attention to the comparison of prognosis between the two groups. Our study suggests that the NST is necessary for the proper administration of nutrition intervention for the hospitalized esophageal cancer patients with RCT to achieve the best therapeutic effect.</p><sec id="sec2-9"><title>Financial support and sponsorship</title><p>This work was supported by a grant of the National High-Tech Research and Development Program (863 Program) (No. 2014AA022206).</p></sec><sec id="sec2-10"><title>Conflicts of interest</title><p>There are no conflicts of interest.</p></sec></sec></body><back><ack><title>Acknowledgments</title><p>We thank the Asia-Pacific Cancer Research Fund for giving a great support from the establishment of our NST to the implementation of this research. We also thank Dr. Han-Ping Shi for research advice.</p></ack><fn-group><fn fn-type="edited-by"><p><bold>Edited by:</bold> Yuan-Yuan Ji</p></fn></fn-group><ref-list><title>R<sc>EFERENCES</sc></title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Hagen</surname><given-names>P</given-names></name><name><surname>Hulshof</surname><given-names>MC</given-names></name><name><surname>van Lanschot</surname><given-names>JJ</given-names></name><name><surname>Steyerberg</surname><given-names>EW</given-names></name><name><surname>van Berge</surname><given-names>Henegouwen MI</given-names></name><name><surname>Wijnhoven</surname><given-names>BP</given-names></name><etal/></person-group><article-title>Preoperative chemoradiotherapy for esophageal or junctional cancer</article-title><source>N Engl J Med</source><year>2012</year><volume>366</volume><fpage>2074</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">22646630</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lloyd</surname><given-names>S</given-names></name><name><surname>Chang</surname><given-names>BW</given-names></name></person-group><article-title>Current strategies in chemoradiation for esophageal cancer</article-title><source>J Gastrointest Oncol</source><year>2014</year><volume>5</volume><fpage>156</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">24982764</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riccardi</surname><given-names>D</given-names></name><name><surname>Allen</surname><given-names>K</given-names></name></person-group><article-title>Nutritional management of patients with esophageal and esophagogastric junction cancer</article-title><source>Cancer Control</source><year>1999</year><volume>6</volume><fpage>64</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">10758536</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Fiore</surname><given-names>F</given-names></name><name><surname>Lecleire</surname><given-names>S</given-names></name><name><surname>Pop</surname><given-names>D</given-names></name><name><surname>Rigal</surname><given-names>O</given-names></name><name><surname>Hamidou</surname><given-names>H</given-names></name><name><surname>Paillot</surname><given-names>B</given-names></name><etal/></person-group><article-title>Baseline nutritional status is predictive of response to treatment and survival in patients treated by definitive chemoradiotherapy for a locally advanced esophageal cancer</article-title><source>Am J Gastroenterol</source><year>2007</year><volume>102</volume><fpage>2557</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">17680847</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larrea</surname><given-names>J</given-names></name><name><surname>Vega</surname><given-names>S</given-names></name><name><surname>Mart&#x000ed;nez</surname><given-names>T</given-names></name><name><surname>Torrent</surname><given-names>JM</given-names></name><name><surname>Vega</surname><given-names>V</given-names></name><name><surname>N&#x000fa;&#x000f1;ez</surname><given-names>V</given-names></name></person-group><article-title>The nutritional status and immunological situation of cancer patients</article-title><source>Nutr Hosp</source><year>1992</year><volume>7</volume><fpage>178</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">1623048</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andreyev</surname><given-names>HJ</given-names></name><name><surname>Norman</surname><given-names>AR</given-names></name><name><surname>Oates</surname><given-names>J</given-names></name><name><surname>Cunningham</surname><given-names>D</given-names></name></person-group><article-title>Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies?</article-title><source>Eur J Cancer</source><year>1998</year><volume>34</volume><fpage>503</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">9713300</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bollschweiler</surname><given-names>E</given-names></name><name><surname>Herbold</surname><given-names>T</given-names></name><name><surname>Plum</surname><given-names>P</given-names></name><name><surname>H&#x000f6;lscher</surname><given-names>AH</given-names></name></person-group><article-title>Prognostic relevance of nutritional status in patients with advanced esophageal cancer</article-title><source>Expert Rev Anticancer Ther</source><year>2013</year><volume>13</volume><fpage>275</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">23477514</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vasson</surname><given-names>MP</given-names></name><name><surname>Talvas</surname><given-names>J</given-names></name><name><surname>Perche</surname><given-names>O</given-names></name><name><surname>Dillies</surname><given-names>AF</given-names></name><name><surname>Bachmann</surname><given-names>P</given-names></name><name><surname>Pezet</surname><given-names>D</given-names></name><etal/></person-group><article-title>Immunonutrition improves functional capacities in head and neck and esophageal cancer patients undergoing radiochemotherapy: A randomized clinical trial</article-title><source>Clin Nutr</source><year>2014</year><volume>33</volume><fpage>204</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">23849811</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shang</surname><given-names>E</given-names></name><name><surname>Hasenberg</surname><given-names>T</given-names></name><name><surname>Schlegel</surname><given-names>B</given-names></name><name><surname>Sterchi</surname><given-names>AB</given-names></name><name><surname>Schindler</surname><given-names>K</given-names></name><name><surname>Druml</surname><given-names>W</given-names></name><etal/></person-group><article-title>An European survey of structure and organisation of nutrition support teams in Germany, Austria and Switzerland</article-title><source>Clin Nutr</source><year>2005</year><volume>24</volume><fpage>1005</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">16143430</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trotti</surname><given-names>A</given-names></name><name><surname>Colevas</surname><given-names>AD</given-names></name><name><surname>Setser</surname><given-names>A</given-names></name><name><surname>Rusch</surname><given-names>V</given-names></name><name><surname>Jaques</surname><given-names>D</given-names></name><name><surname>Budach</surname><given-names>V</given-names></name><etal/></person-group><article-title>CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment</article-title><source>Semin Radiat Oncol</source><year>2003</year><volume>13</volume><fpage>176</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">12903007</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>H&#x000e9;buterne</surname><given-names>X</given-names></name><name><surname>Lemari&#x000e9;</surname><given-names>E</given-names></name><name><surname>Michallet</surname><given-names>M</given-names></name><name><surname>de Montreuil</surname><given-names>CB</given-names></name><name><surname>Schneider</surname><given-names>SM</given-names></name><name><surname>Goldwasser</surname><given-names>F</given-names></name></person-group><article-title>Prevalence of malnutrition and current use of nutrition support in patients with cancer</article-title><source>JPEN J Parenter Enteral Nutr</source><year>2014</year><volume>38</volume><fpage>196</fpage><lpage>204</lpage><pub-id pub-id-type="pmid">24748626</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eades</surname><given-names>M</given-names></name><name><surname>Murphy</surname><given-names>J</given-names></name><name><surname>Carney</surname><given-names>S</given-names></name><name><surname>Amdouni</surname><given-names>S</given-names></name><name><surname>Lemoignan</surname><given-names>J</given-names></name><name><surname>Jelowicki</surname><given-names>M</given-names></name><etal/></person-group><article-title>Effect of an interdisciplinary rehabilitation program on quality of life in patients with head and neck cancer: Review of clinical experience</article-title><source>Head Neck</source><year>2013</year><volume>35</volume><fpage>343</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">22422558</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>P</given-names></name><name><surname>Tao</surname><given-names>G</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name></person-group><article-title>Subjective global assessment and prealbumin levels of esophageal cancer patients undergoing concurrent chemoradiotherapy</article-title><source>Nutr Hosp</source><year>2015</year><volume>31</volume><fpage>2167</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">25929389</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Norman</surname><given-names>K</given-names></name><name><surname>Pichard</surname><given-names>C</given-names></name><name><surname>Lochs</surname><given-names>H</given-names></name><name><surname>Pirlich</surname><given-names>M</given-names></name></person-group><article-title>Prognostic impact of disease-related malnutrition</article-title><source>Clin Nutr</source><year>2008</year><volume>27</volume><fpage>5</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">18061312</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arends</surname><given-names>J</given-names></name><name><surname>Bodoky</surname><given-names>G</given-names></name><name><surname>Bozzetti</surname><given-names>F</given-names></name><name><surname>Fearon</surname><given-names>K</given-names></name><name><surname>Muscaritoli</surname><given-names>M</given-names></name><name><surname>Selga</surname><given-names>G</given-names></name><etal/></person-group><article-title>ESPEN guidelines on enteral nutrition: Non-surgical oncology</article-title><source>Clin Nutr</source><year>2006</year><volume>25</volume><fpage>245</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">16697500</pub-id></element-citation></ref></ref-list></back></article>